Milestones in Personalized Medicine in Pemphigus and Pemphigoid

被引:21
作者
Bieber, Katja [1 ,2 ]
Kridin, Khalaf [1 ,2 ]
Emtenani, Shirin [1 ,2 ]
Boch, Katharina [2 ,3 ]
Schmidt, Enno [1 ,2 ,3 ]
Ludwig, Ralf J. [1 ,2 ,3 ]
机构
[1] Univ Lubeck, Lubeck Inst Expt Dermatol, Lubeck, Germany
[2] Univ Lubeck, Ctr Res Inflammat Skin, Lubeck, Germany
[3] Univ Lubeck, Dept Dermatol, Lubeck, Germany
关键词
precision medicine; pemphigus; pemphigoid; diagnosis; treatment; EPIDERMOLYSIS-BULLOSA-ACQUISITA; SERRATION PATTERN-ANALYSIS; BLISTER FORMATION; PASSIVE TRANSFER; JEWISH PATIENTS; VULGARIS; COMPLEMENT; AUTOANTIBODIES; ANTIGEN; DISEASES;
D O I
10.3389/fimmu.2020.591971
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pemphigus and pemphigoid diseases are autoimmune bullous diseases characterized and caused by autoantibodies targeting adhesion molecules in the skin and/or mucous membranes. Personalized medicine is a new medical model that separates patients into different groups and aims to tailor medical decisions, practices, and interventions based on the individual patient`s predicted response or risk factors. An important milestone in personalized medicine in pemphigus and pemphigoid was achieved by verifying the autoimmune pathogenesis underlying these diseases, as well as by identifying and cloning several pemphigus/pemphigoid autoantigens. The latter has become the basis of the current, molecular-based diagnosis that allows the differentiation of about a dozen pemphigus and pemphigoid entities. The importance of autoantigen-identification in pemphigus/pemphigoid is further highlighted by the emergence of autoantigen-specific B cell depleting strategies. To achieve this goal, the chimeric antigen receptor (CAR) T cell technology, which is used for the treatment of certain hematological malignancies, was adopted, by generating chimeric autoantigen receptor (CAAR) T cells. In addition to these more basic science-driven milestones in personalized medicine in pemphigus and pemphigoid, careful clinical observation and epidemiology are again contributing to personalized medicine. The identification of clearly distinct clinical phenotypes in pemphigoid like the non-inflammatory and gliptin-associated bullous pemphigoid embodies a prominent instance of the latter. We here review these exciting developments in basic, translational, clinical, and epidemiological research in pemphigus and pemphigoid. Overall, we hereby aim to attract more researchers and clinicians to this highly interesting and dynamic field of research.
引用
收藏
页数:10
相关论文
共 107 条
[1]   A unique form of endemic pemphigus in northern Colombia [J].
Abrèu-Velez, AM ;
Hashimoto, T ;
Bollag, WB ;
Arroyave, ST ;
Abrèu-Velez, CE ;
Londoño, ML ;
Montoya, F ;
Beutner, EH .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (04) :599-608
[2]   MAJOR HISTOCOMPATIBILITY COMPLEX HAPLOTYPES AND CLASS-II GENES IN NON-JEWISH PATIENTS WITH PEMPHIGUS VULGARIS [J].
AHMED, AR ;
WAGNER, R ;
KHATRI, K ;
NOTANI, G ;
AWDEH, Z ;
ALPER, CA ;
YUNIS, EJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (11) :5056-5060
[3]   AUTOANTIBODIES AGAINST A NOVEL EPITHELIAL CADHERIN IN PEMPHIGUS-VULGARIS, A DISEASE OF CELL-ADHESION [J].
AMAGAI, M ;
KLAUSKOVTUN, V ;
STANLEY, JR .
CELL, 1991, 67 (05) :869-877
[4]  
Anhalt G J, 1987, Clin Dermatol, V5, P117, DOI 10.1016/0738-081X(87)90056-3
[5]   INDUCTION OF PEMPHIGUS IN NEONATAL MICE BY PASSIVE TRANSFER OF IGG FROM PATIENTS WITH THE DISEASE [J].
ANHALT, GJ ;
LABIB, RS ;
VOORHEES, JJ ;
BEALS, TF ;
DIAZ, LA .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (20) :1189-1196
[6]   A Case Report of Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors [J].
Aouidad, Iman ;
Fite, Charlotte ;
Marinho, Eduardo ;
Deschamps, Lydia ;
Crickx, Beatrice ;
Descamps, Vincent .
JAMA DERMATOLOGY, 2013, 149 (02) :243-245
[7]   The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy [J].
Buijsrogge, J. J. A. ;
Diercks, G. F. H. ;
Pas, H. H. ;
Jonkman, M. F. .
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (01) :92-98
[8]  
Burmester Imke A K, 2019, Curr Protoc Pharmacol, V85, pe56, DOI 10.1002/cpph.56
[9]   IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid [J].
Chakievska, Lenche ;
Holtsche, Maike M. ;
Kuenstner, Axel ;
Goletz, Stephanie ;
Petersen, Britt-Sabina ;
Thaci, Diamant ;
Ibrahim, Saleh M. ;
Ludwig, Ralf J. ;
Franke, Andre ;
Sadik, Christian D. ;
Zillikens, Detlef ;
Hoelscher, Christoph ;
Busch, Hauke ;
Schmidt, Enno .
JOURNAL OF AUTOIMMUNITY, 2019, 96 :104-112
[10]   Synergy among non-desmoglein antibodies contributes to the immunopathology of desmoglein antibody-negative pemphigus vulgaris [J].
Chernyavsky, Alex ;
Amber, Kyle T. ;
Agnoletti, Arianna F. ;
Wang, Candice ;
Grando, Sergei A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (12) :4520-4528